Cargando…
Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics
Background: Ovarian carcinoma is a common malignant tumor of the female reproductive organs with an incidence rate second only to cervical and endometrial cancers. In the past 10 years, anticancer therapy has focused on Niclosamide, an anthelmintic teniacide that is commonly used against tapeworms a...
Autores principales: | Shangguan, Fugen, Liu, Yan, Ma, Li, Qu, Guiwu, Lv, Qing, An, Jing, Yang, Shude, Lu, Bin, Cao, Qizhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150452/ https://www.ncbi.nlm.nih.gov/pubmed/32284741 http://dx.doi.org/10.7150/jca.41418 |
Ejemplares similares
-
LAIR-1 suppresses cell growth of ovarian cancer cell via the PI3K-AKT-mTOR pathway
por: Liu, Yan, et al.
Publicado: (2020) -
Bioenergetic modulation with the mitochondria uncouplers SR4 and niclosamide prevents proliferation and growth of treatment-naïve and vemurafenib-resistant melanomas
por: Figarola, James L., et al.
Publicado: (2018) -
A novel mechanism of 6-methoxydihydroavicine in suppressing ovarian carcinoma by disrupting mitochondrial homeostasis and triggering ROS/ MAPK mediated apoptosis
por: Zhang, Huachang, et al.
Publicado: (2023) -
Five ETS family members, ELF-1, ETV-4, ETV-3L, ETS-1, and ETS-2 upregulate human leukocyte-associated immunoglobulin-like receptor-1 gene basic promoter activity
por: Cao, Qizhi, et al.
Publicado: (2018) -
Niclosamide and its derivative DK‐520 inhibit RANKL‐induced osteoclastogenesis
por: Jiao, Yurui, et al.
Publicado: (2020)